USFDA issues 6 observations after inspection of Aurobindo Pharma's Jedcherla facility
"The Company will respond to the USFDA within the stipulated timeline and work closely with USFDA to close the observations," the company added.;
Advertisement
Hyderabad: Drugmaker, Aurobindo Pharma, has recently announced that the United States Food and Drug Administration (USFDA) has concluded an inspection with six observations at its Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad.
The inspection was conducted from 2nd to 10th May 2022.
"USFDA inspected Company's Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, from 2nd to 10th May 2022. At the end of the inspection, we have been issued a 'Form 483' with six observations," Aurobindo Pharma said in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.